Skip to main content
Protagenic Therapeutics, Inc.\new logo

Protagenic Therapeutics, Inc.\new — Investor Relations & Filings

Ticker · PTIX ISIN · US74365N2027 LEI · 549300KPBYAVJLPDKB70 US Professional, scientific and technical activities
Open in API
Filings indexed 678 across all filing types
Latest filing 2023-02-14 Major Shareholding Noti…
Country US United States of America
Listing US PTIX

About Protagenic Therapeutics, Inc.\new

https://protagenic.com/

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics for stress-related disorders. The company's core technology is its TCAP (teneurin C-terminal associated peptide) platform, which utilizes neuropeptides to regulate the brain's stress response at a cellular level. This approach aims to counteract the 'Stress Feedback Loop' implicated in various neuropsychiatric and neurodegenerative conditions. Its lead drug candidate, PT00114, a synthetic TCAP, is being developed as a potential first-in-class treatment for disorders such as anxiety and depression.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-14 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. It includes detailed voting results from the company's 2022 Annual Meeting of Stockholders, including election of directors, approval of a reverse stock split amendment, ratification of the independent auditor, and advisory vote on executive compensation. It also provides a business update on regulatory progress for a clinical trial. The presence of detailed voting results from the Annual Meeting clearly indicates this is a Declaration of Voting Results & Voting Rights Announcement. The document is not an Annual Report, Audit Report, or Management Report, nor is it a simple announcement or proxy solicitation. The length and content confirm it is the actual voting results report, not just an announcement of a report. Therefore, the correct classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2022-11-29 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Q3 2022
2022-11-14 English
Proxy Solicitation & Information Statement 2022
Proxy Solicitation & Information Statement
2022-10-12 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports an event on August 30, 2022, specifically about receiving regulatory questions from a European authority and plans for clinical trials and US submission. The document is short (2690 characters) and does not contain financial statements or detailed financial analysis. It is an event update rather than a full financial report or earnings release. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-09-02 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Q2 2022
2022-08-11 English

Browse filings by year

30 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.